Neoadjuvant Immunotherapy in EGFR-mutant Localized NSCLC
Status:
Not yet recruiting
Trial end date:
2025-05-01
Target enrollment:
Participant gender:
Summary
Phase II, single-arm, open-label multicenter study that assess clinical feasibility and
safety of 3 cycles neoadjuvant Sintilimab plus chemotherapy in EGFR-mutant stage II-IIIB
NSCLC followed by optional adjuvant treatment upon investigators' decisions.